Mural Oncology Files Definitive Additional Materials

TL;DR

Mural Oncology dropped more official docs, check the proxy statement details.

AI Summary

Mural Oncology plc filed a DEFA14A, indicating it is a definitive additional material filing. The company, formerly known as Mural Oncology Ltd and Pistachiovale Ltd, is incorporated in L2 and has its fiscal year end on December 31st. The filing is related to proxy statements and is not a preliminary filing or soliciting material under Rule 14a-12.

Why It Matters

This filing indicates that Mural Oncology is providing further official documentation to shareholders, likely related to upcoming corporate actions or decisions requiring shareholder approval.

Risk Assessment

Risk Level: low — This filing is a routine administrative document (DEFA14A) and does not inherently present new financial or operational risks.

Key Players & Entities

• Mural Oncology plc (company) — Registrant
• Mural Oncology Ltd (company) — Former company name
• Pistachiovale Ltd (company) — Former company name

FAQ

Filing Documents

• d32744ddefa14a.htm (DEFA14A) — 30KB
• g32744dsp1.jpg (GRAPHIC) — 9KB
• 0001193125-25-213602.txt ( ) — 44KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under Rule 14a-12 Mural Oncology plc (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee previously paid with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting September 23, 2025 WALTHAM, Mass. and DUBLIN, Ireland, September 23, 2025 (GLOBE NEWSWIRE)– Mural Oncology plc, (Nasdaq: MURA) (" Mural "), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the " Irish Takeover Rules "), that it has published the definitive proxy statement of Mural relating to the Acquisition described below, which also constitutes a scheme circular under Irish law (the " Proxy Statement ") and that Mural has commenced mailing the Proxy Statement to Mural shareholders. As previously announced on August 20, 2025, XOMA Royalty Corporation (Nasdaq: XOMA) (" XOMA Royalty ") and Mural entered into a definitive transaction agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty (" Sub "), has agreed to acquire the entire issued and to be issued share capital of Mural (the " Acquisition ") pursuant to an Irish High Court sanctioned "scheme of arrangement" under Chapter 1 of Part 9 of the Irish Companies Act of 2014 (the " Scheme "). The Proxy Statement contains important information about the Acquisition for Mural shareholders including, among other things, the full terms and conditions of the Acquisition, instructions on how Mural shareholders may attend the meetings and vote in respect of the Acquisition, information required under Section 452 of the Irish Companies Act 2014 and details of the actions to be taken by Mural shareholders in relation to the Scheme. In accordance with Rule 15(c) of the Irish Takeover Rules, the holders of Mural equity awards have been sent a proposal describing the treatment of the Mural equity awards in the Acquisition. A copy of the Proxy Statement is also being sent to the holders of Mural equity awards with the Rule 15 proposal for informational purposes only. Copies of the documents referred to above, and all of the documents required to be made available in accordance with Rule 26 of the Irish Takeover Rules, are available on Mural's website at https://ir.muraloncology.com/strategic-review. Further, notices convening the scheme meeting of Mural shareholders to consider and vote on the Scheme (the " Scheme Meeting ") and the related extraordinary general meeting (the " EGM ") are contained in the Proxy Statement. The Scheme Meeting will be held on October 24, 2025 at 10:30 a.m. Irish local time. Following this meeting, the EGM will be held at 10:45 a.m. Irish local time (or, if the Scheme Meeting has not concluded by 10:45 a.m. Irish local time, as soon as possible after the conclusion or adjournment of the Scheme Meeting). Both the Scheme Meeting and the EGM will be held at Ten Earlsfort Terrace, Dublin 2, D02 T380, Ireland. About Mural Mural Oncology plc is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. On March 25, 2025, Mural announced that, based on the interim analysis of results, its Phase 3 ARTISTRY-7 trial of nemvaleukin alfa ("nemvaleukin") in combination with pembrolizumab did not achieve its primary endpoint of a statistically significant improvement in overall survival versus investigator's choice chemotherapy. Mural also announced that ARTISTRY-7 would not continue to final analysis and Mural would cease development of nemvaleukin for platinum resistant ovarian cancer. On April 15, 2025, Mural announced that following review of data from its Phase 2 ARTISTRY-6 trial of nemvaleukin in mucosal and cutaneous melanoma and the previously announced results from the ARTISTRY-7 trial, Mural was discontinuing all clinical development of nemvaleukin and planned to immediately commence an exploration of strategic alternatives focused on maximizing shareholder value. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Wal

View Full Filing

View this DEFA14A filing on SEC EDGAR